Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMEGA: Local Ablative Therapy in Oligometastatic NSCLC
NCT03827577Phase 3Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Overall Survival at 60 months. Status: unknown.
Beyond the preview
Go deeper on NCT03827577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827577.